Buy Crypto
Pay with
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Markets
Trade
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
U.S. Stocks
CFD
U.S. stock CFD derivatives
Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
GUSD
Mint GUSD for Treasury RWA yields
Earn
Launch
CandyDrop
tag
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investment
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
More
Promotions
AI
Others
TradFi
Rewards
Square
Latest
Hot
News
Profile

Health Yuan: Lizhu monoclonal antibody recombinant human follicle-stimulating hormone injection approved for registration; research and development expenses are approximately 122 million yuan

K-LinePoet
robot
Abstract generation in progress
Health Yuan announced that recently, its subsidiary Zhuhai Lijubantibody Biotechnology Co., Ltd., a subsidiary of Lijubao Pharmaceutical Group Co., Ltd., received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration. The generic name of the drug is recombinant human follicle-stimulating hormone injection, and the trade name is Liyoubao. The indications are for women with anovulation, women undergoing superovulation in assisted reproductive technology, and patients with severe deficiency of luteinizing hormone and follicle-stimulating hormone. This product is produced using recombinant gene technology, and has completed clinical Phase I to III evaluations of biosimilar drugs, demonstrating equivalence to the original drug. As of the announcement date, the total direct R&D expenses invested in this product are approximately 122 million yuan.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments

  • Pinned

Sitemap